Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
Xin Miao(Johnson & Johnson (United States)), Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Lixia Pei(Nanjing University of Chinese Medicine), Yuki Iwaki, Mahesh N. Samtani(Janssen (United States)), Danièle Ouellet(Janssen (United States)), Kathleen T. Hickey(Janssen (United States)), Danielle Trancucci(Centre Hospitalier Universitaire de Nantes), Kristy Kemmerer(Janssen (United States)), Honghui Zhou(Janssen (United States)), Alfred L. Garfall(University of Pennsylvania), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Yan Xu(University of California, Berkeley), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Clarissa Uhlar(University of Pennsylvania), Rachit Desai(Janssen (United States)), Yang Chen(Janssen (United States)), Yue Guo(Janssen (United States)), Liviawati S. Wu(Janssen (United States)), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Amit Apte(Janssen (United States)), Yaming Su(Janssen (United States)), Amrita Krishnan(City of Hope), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center)
Cited by 46
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Serum amyloid A, the major vertebrate acute‐phase reactant
|European Journal of Biochemistry|1999|1.1k